Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis
Background and Objective Janus kinase (JAK) inhibitors (JAKinibs) are effective for inflammatory bowel disease (IBD), but their cardiovascular safety is inconclusive. We aim to assess the cardiovascular risks associated with JAKinibs in IBD patients.Patients and Methods Systematic searches of seven...
Saved in:
Main Authors: | Huibin Yang, Ting An, Yuxuan Zhao, Xiaojing Shi, Bangmao Wang, Qingyu Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2025-12-01
|
Series: | Annals of Medicine |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2025.2455536 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?
by: Yachar Dawudi, et al.
Published: (2025-01-01) -
Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review
by: Yu Liu, et al.
Published: (2025-12-01) -
Increased risk of Pneumocystis jirovecii colonization in rheumatoid arthritis patients on biologics and Janus kinase inhibitor
by: Ya-Chun Huang, et al.
Published: (2025-02-01) -
Role of Janus Kinase inhibitors in the management of pulmonary involvement due to Long COVID-19 disease: A case control study
by: Pawan Kumar Singh, et al.
Published: (2023-07-01) -
Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
by: Jiao Wang, et al.
Published: (2025-02-01)